Drugs / BAY1436032
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03127735 | Jun 2017 → Dec 2018 | acute myeloid leukemia | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02746081 | May 2016 → Nov 2018 | cancer | Bayer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1436032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02746081 ↗ |
| Action | Inhibit | “Oral Mutant IDH1 Inhibitor BAY1436032” NCT02746081 ↗ |
| Modality | Small molecule | — CHEMBL4206033 ↗ |
| Route | Oral | “to be administered orally continuously in tablet form” NCT02746081 ↗ |
| Target | IDH1 | “Oral Mutant IDH1 Inhibitor BAY1436032” NCT02746081 ↗ |